Kidney Sodium Content in Cardiorenal Patients
Cardio-Renal Syndrome
About this trial
This is an interventional diagnostic trial for Cardio-Renal Syndrome focused on measuring kidney sodium content, Sodium MRI
Eligibility Criteria
Inclusion Criteria for Visit 1
- Clinico-pathological diagnosis of heart failure
- Age ≥ 18 years
- Estimated GFR ≥ 15 mL/min/1.73m2
- Receiving loop diuretics for at least a week at ≥ 40 mg/day (furosemide) or 2 mg/day (bumetanide), either orally or intravenously
- Willing and able to provide consent
Inclusion Criteria for Visit 2 · Patients from visit 1 with diuretic resistance
Exclusion Criteria for Visit 1 Direct contraindications to MR scanning (implanted materials etc.)
- Additional diuretic types other than spironolactone/epleronone/metolazone/finerenone
- Liver disease with hepato-renal syndrome
- Pregnant, breastfeeding or intending pregnancy
- Kidney malformation leading to chronic kidney disease (for example polycystic kidney)
- Unable to provide consent
Exclusion criteria for Visit 2
· Hypokalemia (serum potassium <3.5 mmol/l)
Sites / Locations
- Heart Failure Clinic | St. Joseph's Health Care LondonRecruiting
Arms of the Study
Arm 1
Other
Furosemide Injection
Patients with diuretic resistance: The presence of diuretic resistance, defined as having clinical signs of fluid overload despite diuretic therapy (this information is routinely collected at each clinical visit). "Fluid overload" is defined as the presence of at least two of the following clinical features: Peripheral or sacral oedema Jugular venous distension ≥ 7 cm Radiographic pulmonary oedema or pleural effusion Enlarged liver or ascites Pulmonary rales, paroxysmal nocturnal dyspnoea, or orthopnoea Point of Care UltraSound (POCUS) evidence of congestion. Inferior Vena Cava diameter >2.5 cm and/or failure to collapse at least 50% with sharp inspiration